Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway

Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway

Cholangiocarcinoma is the most common primary malignant tumor of the bile duct. The current standard first-line treatment for advanced or metastatic cholangiocarcinoma is gemcitabine and cisplatin. However, few effective treatment choices exist for refractory cholangiocarcinoma, and additional thera...

Full description

Bibliographic Details
Main Authors: Shin-Yi Chung, Yi-Ping Hung, Yi-Ru Pan, Yu-Chan Chang, Chiao-En Wu, Dennis Shin-Shian Hsu, Peter Mu-Hsin Chang, Meng-Lun Lu, Chi-Ying F. Huang, Yeu Su, Michael Hsiao, Chun-Nan Yeh, Ming-Huang Chen
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Biomedicines
Subjects:
cholangiocarcinoma
ALDH1A3
JAK2 inhibitor
STATs
ruxolitinib
Online Access:https://www.mdpi.com/2227-9059/9/8/885

Internet

https://www.mdpi.com/2227-9059/9/8/885

Similar Items